Date published: 2025-12-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

Oridonin, R. rubescens (CAS 28957-04-2)

0.0(0)
Write a reviewAsk a question

Application:
Oridonin, R. rubescens is a diterpenoid showing anti NF-κB, antiproliferative and antiangiogenic properties
CAS Number:
28957-04-2
Molecular Weight:
364.4
Molecular Formula:
C20H28O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Oridonin is a diterpenoid compound found in Rabdosia rubescens. It functions as an inhibitor of cell proliferation and inducer of apoptosis in various cancer cell lines. Oridonin exerts its mode of action by targeting multiple signaling pathways involved in cell growth and survival, including the NF-κB pathway, PI3K/Akt pathway, and MAPK pathway. Oridonin exhibits anti-inflammatory properties by suppressing the production of pro-inflammatory cytokines and inhibiting the activation of inflammatory transcription factors. Oridonin may modulate the expression of genes involved in angiogenesis, metastasis, and resistance in cancer cells. Its ability to interfere with multiple cellular processes makes it a useful for investigating the molecular mechanisms underlying cancer progression and for exploring strategies.


Oridonin, R. rubescens (CAS 28957-04-2) References

  1. Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES.  |  Meade-Tollin, LC., et al. 2004. J Nat Prod. 67: 2-4. PMID: 14738375
  2. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways.  |  Ikezoe, T., et al. 2005. Mol Cancer Ther. 4: 578-86. PMID: 15827331
  3. Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies.  |  Zhao, Z. and Chen, Y. 2014. Curr Pharm Biotechnol. 15: 1083-92. PMID: 25391243
  4. Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.  |  Li, D., et al. 2016. Int J Mol Sci. 17: PMID: 27563888
  5. Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities.  |  Cheng, W., et al. 2019. Mini Rev Med Chem. 19: 114-124. PMID: 28425866
  6. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.  |  He, H., et al. 2018. Nat Commun. 9: 2550. PMID: 29959312
  7. Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways.  |  Yang, H., et al. 2019. Cell Commun Signal. 17: 62. PMID: 31186013
  8. Solubility and Bioavailability Enhancement of Oridonin: A Review.  |  Zhang, Y., et al. 2020. Molecules. 25: PMID: 31947574
  9. Oridonin Induces Apoptosis of Laryngeal Carcinoma via Endoplasmic Reticulum Stress.  |  Kou, B., et al. 2020. Cancer Manag Res. 12: 8387-8396. PMID: 32982432
  10. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance.  |  Liu, X., et al. 2021. Genes Dis. 8: 448-462. PMID: 34179309
  11. Oridonin Alters Hepatic Urea Cycle via Gut Microbiota and Protects against Acetaminophen-Induced Liver Injury.  |  Hong, MK., et al. 2021. Oxid Med Cell Longev. 2021: 3259238. PMID: 34721757
  12. Oridonin alleviates hyperbilirubinemia through activating LXRα-UGT1A1 axis.  |  Zhan, Z., et al. 2022. Pharmacol Res. 178: 106188. PMID: 35338002
  13. Oridonin Delays Aging Through the AKT Signaling Pathway.  |  An, Y., et al. 2022. Front Pharmacol. 13: 888247. PMID: 35662728
  14. Oridonin attenuates lung inflammation and fibrosis in silicosis via covalent targeting iNOS.  |  Gao, J., et al. 2022. Biomed Pharmacother. 153: 113532. PMID: 36076611
  15. Oridonin Protects against Myocardial Ischemia-Reperfusion Injury by Inhibiting GSDMD-Mediated Pyroptosis.  |  Lin, J., et al. 2022. Genes (Basel). 13: PMID: 36421808

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Oridonin, R. rubescens, 5 mg

sc-202751
5 mg
$77.00